Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
1301
Pan-cancer analyses of ANGPTL4 expression and its prognostic significance in the TCGA database.
Published 2025Subjects: -
1302
Pan-cancer analyses of NFKB2 expression and its prognostic significance in the TCGA database.
Published 2025Subjects: -
1303
-
1304
-
1305
-
1306
-
1307
-
1308
Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX
Published 2024“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”
-
1309
Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX
Published 2024“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”
-
1310
Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1311
Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1312
Shares of specialist groups prescribing 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019.
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1313
Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0).
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1314
Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1315
Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription.
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1316
UTI diagnoses by sex and physician specialty (2013–2019).
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1317
Advantages of Novel Anti-cancer Selenosemicarbazones: Preferential Reactivity of Their Fe(III), Cu(II), and Zn(II) Complexes with Key Physiological Reductants/Ligands Versus Isoste...
Published 2025“…The role of glutathione in all three latter reactions is significant, given the greater reactivity of the selenosemicarbazone, and glutathione’s key role in selenosemicarbazone and thiosemicarbazone anticancer activity.…”
-
1318
Advantages of Novel Anti-cancer Selenosemicarbazones: Preferential Reactivity of Their Fe(III), Cu(II), and Zn(II) Complexes with Key Physiological Reductants/Ligands Versus Isoste...
Published 2025“…The role of glutathione in all three latter reactions is significant, given the greater reactivity of the selenosemicarbazone, and glutathione’s key role in selenosemicarbazone and thiosemicarbazone anticancer activity.…”
-
1319
-
1320
Additional file 3 of Single-cell profiling reveals a reduced epithelial defense system, decreased immune responses and the immune regulatory roles of different fibroblast subpopula...
Published 2025“…P values were calculated via the two-sided Wilcoxon test. ns, not significant, **, P < 0.01 and ****, P < 0.0001. (G) Feature plot showing LDLR expression levels in C1Q+ macrophages between CAG and control samples.…”